MedDataX Logo

Paracetamol Metabolism in Post Operative Conditions

NCT ID: NCT01152502

Last Updated: 2010-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-06-30

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Follow-up of urinary concentration from paracetamol metabolites by patients with aortic surgery during 4 days therapeutic intake (perfalgan ® 4 x 1g IV/day)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

D-15 to D0: selection

* patient information and non-opposition obtained
* inclusion and non inclusion criteria check
* clinical exam

D-1 to D0 : 24 hours diuresis

D0 : operation day

Before anesthesia :

* urine collection (paracetamol metabolites dosage)
* blood sampling (glutathion and liver function test)

Surgery:

* 1st paracetamol intake before closing
* Then administration every 6 hours

D1 to D4 :

* 24 hours urine collection (metabolites dosage)
* blood sampling et D1 and D4(glutathion and liver function test)

D5 : final clinical exam

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Surgery and Treatment Post Operative With Paracetamol During 4 Days

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Post operative conditions, paracetamol metabolites

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* aortic surgery
* treatment with intraveinous paracetamol (4 grammes daily during 4 days)
* patient agrees to participate

Exclusion Criteria

* \- patient disagrees
* paracetamol contra-indication
* paracetamol intake 5 days before surgery
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Clermont-Ferrand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

CHU Clermont-Ferrand

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric SCHNEIDER

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHU-0076

Identifier Type: -

Identifier Source: org_study_id